Novartis’ Gleevec lowers risk of leukemia progression in study

Share this article:
Novartis said Monday that a new study showed the longer patients with a certain form of chronic myeloid leukemia took its Gleevec pill, the lower the risk that their cancer was progressing to the advanced phases of the disease, The Wall Street Journal reports.
The study, presented at the American Society of Hematology meeting in Atlanta, comprises 1,106 patients newly diagnosed with Philadelphia chromosome-positive chronic myeloid leukemia. It also showed that after 54 months, more than 90% of patients receiving Gleevec were still alive. Chronic myeloid leukemia, or CML, is a slowly progressing cancer that makes the body produce too many cancerous myeloid white blood cells.
Gleevec is Novartis' second-best selling product behind high-blood pressure treatment Diovan.
Sales of Gleevec rose 35% in the nine months to Sept. 30, to $1.6 billion.
Share this article:
close

Next Article in News

Email Newsletters

More in News

Doctors want to know how CMS plans to display Sunshine payment data

Doctors want to know how CMS plans to ...

Physician and industry trade groups are asking CMS to explain how context will be provided to the general public around the dollar sums drugmakers ascribe to doctors for things like ...

Pfizer Q2 sales slip, but still beat expectations

Pfizer Q2 sales slip, but still beat expectations

Patent losses and lost co-promotion agreements put a dent in sales.

Lack of marketing partner delays Afrezza launch

Lack of marketing partner delays Afrezza launch

Afrezza was heralded as one of the most innovative diabetes products of the last decade. So, why hasn't MannKind set a firm launch date for the product?